Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice

Neurosci Lett. 2006 Jan 23;393(1):31-5. doi: 10.1016/j.neulet.2005.09.036. Epub 2005 Oct 17.

Abstract

Adenosine A(2A) receptor (A(2A)R) antagonists, including the non-specific adenosine antagonist caffeine, have been proposed as a novel, non-dopaminergic treatment strategy for Parkinson's disease (PD). However, the long-term interaction between caffeine and L-dopa treatment in PD models has not been characterized. We examined the interaction between caffeine and L-dopa following a repeated treatment paradigm in hemiparkinsonian mice. In contrast to the progressively sensitized rotational behavior induced by daily L-dopa (2.0 mg/kg) treatment, tolerance for the rotational response to daily caffeine (2.5 or 10 mg/kg) treatment tended to develop over several weeks. However, after a subsequent two-week washout, challenge with same drug demonstrated an extinction of the sensitized L-dopa-induced rotation, but a sensitization of the caffeine-induced rotation. In a cross-challenge paradigm, daily treatment of mice with L-dopa (compared to daily saline) produced a three-fold enhancement in the rotational response to a subsequent re-challenge with caffeine. Similarly, daily treatment of mice with caffeine produced a six-fold enhancement in the rotational response to a subsequent re-challenge with L-dopa. Furthermore, daily co-administration of caffeine plus L-dopa produced enhanced rotational behavior, compared to caffeine or L-dopa alone, indicating an additive or synergistic interaction between caffeine and L-dopa during repeated treatment. Cross-sensitization between caffeine and L-dopa following repeated treatment and their positive interaction during chronic co-adminstration in hemiparkinsonian mice suggest that repeated exposure to caffeine may alter L-dopa responses in PD.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine A2 Receptor Antagonists*
  • Analysis of Variance
  • Animals
  • Antiparkinson Agents / administration & dosage*
  • Behavior, Animal / drug effects*
  • Caffeine / administration & dosage*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Levodopa / administration & dosage*
  • Mice
  • Mice, Inbred C57BL
  • Oxidopamine
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy*
  • Random Allocation
  • Time Factors

Substances

  • Adenosine A2 Receptor Antagonists
  • Antiparkinson Agents
  • Caffeine
  • Levodopa
  • Oxidopamine